REGENERON PHARMACEUTICALS, INC.

Nasdaq: REGN·Tarrytown, New York·

Price
$952.40
Base IV
$782.85

Valuation snapshot

Above base case

At $952.40, the price sits between our base case ($782.85) and bull case ($1,129.13).

Values per share, from an .

No growth
…
Loading earnings power
Base case
$782.85
82% of the price · range $436.30–$1,129.13
Price vs base case
22% above
$952.40 against $782.85
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $436.30 to bull $1,129.13. Values per share.

Price against each value

Bear case
$436.30
Price 118% above
No growth
…
—
Base case
$782.85
Price 22% above
Researched byClaude Opus 5.5
Valuation Nov 13, 2026 · Price as of Nov 16, 2026How we got here

What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals develops and commercializes biologic medicines and therapies to treat various diseases and medical conditions.

It brought in $16.9B of sales in the 12 months to Sep 2026.

Led by Leonard S. Schleifer, MD, PhD, Board Co-Chair, President and Chief Executive Officer (Founder). Leonard S. Schleifer, MD, PhD – Regeneron leadership biography

Dupixent (dupilumab) injectionImage: Sanofi and Regeneron
Industry
Healthcare
Based in
Tarrytown, New York
Trades on
Nasdaq as REGN

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 29¢ was left as profit after every cost, interest and tax. The biggest cost is research and development, 39¢ of every dollar.

  • Research and development39¢
  • Sales, marketing and admin16¢
  • Everything else it takes to operate16¢
  • Tax5¢
  • Left as profit29¢
  • Interest and other income came back in+5¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Regeneron Pharmaceuticals, and for what?

Regeneron discovers, develops, manufactures, and sells medicines for serious diseases, including eye, allergic and inflammatory diseases, and cancer. It earns revenue from product sales and from collaborations, royalties, and manufacturing supplies provided to partners.

Its medicines are sold mainly to wholesalers, specialty distributors, pharmacies, hospitals, government agencies, physicians, and other healthcare providers.

  • Net product sales

    44%

    Sales of products Regeneron records directly, including EYLEA, EYLEA HD, and Libtayo.

  • Sanofi collaboration revenue

    41%

    Mainly Regeneron's share of profits and manufacturing reimbursements from products such as Dupixent and Kevzara.

    Dupixent (dupilumab) injectionImage: Sanofi and Regeneron
  • Bayer collaboration revenue

    10%

    Regeneron's share of profits and manufacturing reimbursements from EYLEA and EYLEA HD sales outside the United States.

  • Other revenue

    5%

    Includes royalties, Regeneron's share of ARCALYST profits, and manufacturing revenue from other parties.

    Arcalyst (rilonacept) injection vialImage: Kiniksa Pharmaceuticals
Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Rensselaer manufacturing campus — Rensselaer, United States. This FDA-approved facility manufactures bulk drug materials and products, with approximately 100,000 liters of cell culture capacity and a fill/finish facility undergoing validation.
  • Limerick manufacturing campus — Limerick, Ireland. This FDA-approved facility manufactures bulk drug materials and products and provides approximately 120,000 liters of cell culture capacity.
  • Saratoga Springs manufacturing facility — Saratoga Springs, United States. The facility is under construction to expand future pharmaceutical manufacturing capacity and has been selected for the FDA PreCheck Pilot Program.
See them on the globe

Regeneron Pharmaceuticals, Inc. 2025 Form 10-K

How is the business doing?

Sales grew from $8.5B in 2020 to $14.3B in 2025, about 11% a year.

Running the business leaves about 29¢ of each sales dollar as operating profit, down from 42¢ in 2020.

After paying for its upkeep and new investment, it had $3.8B of cash to spare in the 12 months to Sep 2026.

Sales$14.3B
20162025
Operating margin25%
20162025
Free cash flow$4.1B
20162025
Each bar is one fiscal year (2016–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

Regeneron says its objective is to provide patients and medical professionals with important medicines to prevent and treat human diseases.

“provide patients and medical professionals with important medicines for preventing and treating human diseases”

Regeneron Pharmaceuticals, Inc. 2025 Form 10-K

Who is responsible for the plan?

Roles checked November 13, 2026.

What management says it is working on now:

What's changing right now?

Growth is picking up. In Q3 2026 it sold 36% more than a year earlier. The year before, quarters averaged 10%.

Its operating margin is wider than a year ago: 40¢ per sales dollar, against 27¢.

Since Oct 2026 the share price has risen 16%, from $818.77 to $952.40.

Bull $1,129.13Base $782.85Bear $436.30Oct 30Nov 16 · $952.40
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

Coming up

  • Second quarter 2026

    FDA decision on EYLEA HD pre-filled syringe

    The FDA is expected to decide on Regeneron's application for an EYLEA HD pre-filled syringe using a new manufacturer.

    Regeneron Pharmaceuticals, Inc. 2025 Form 10-K
  • Second half 2026

    FDA and European Commission decisions on garetosmab

    Regeneron expects regulatory decisions on garetosmab for fibrodysplasia ossificans progressiva after its Phase 3 trial met the main study goal.

    Regeneron Pharmaceuticals, Inc. 2025 Form 10-K
  • Fourth quarter 2026 or first quarter 2027

    Results from Phase 3 study of pozelimab and cemdisiran

    Regeneron expects to report results from a Phase 3 study of the combination in paroxysmal nocturnal hemoglobinuria.

    Regeneron Pharmaceuticals, Inc. 2025 Form 10-K
  • Second half 2026

    Possible U.S. EYLEA biosimilar launches

    Additional biosimilar versions of EYLEA are expected to launch in the United States, potentially adding to competition for EYLEA and EYLEA HD.

    Regeneron Pharmaceuticals, Inc. 2025 Form 10-K

Our own estimate moved too: the base case went from $1,048.20 to $782.85 a share between our last two valuations.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Dependence on a few major medicines

    EYLEA HD, EYLEA, and Dupixent account for a substantial share of the business. EYLEA faces competition and declining sales, and future EYLEA HD growth may not offset that decline.

    From the company's own filingsWould hit how fast sales growRegeneron Pharmaceuticals, Inc. 2025 Form 10-K

  2. Competition and biosimilars

    Rivals may offer medicines that work better, cost less, or are easier to use. Biosimilar versions of EYLEA have launched or may launch, putting pressure on sales and collaboration revenue.

    From the company's own filingsWould hit how fast sales growRegeneron Pharmaceuticals, Inc. 2025 Form 10-K

  3. Drug development and approval uncertainty

    Clinical studies can fail to show benefits or reveal safety issues, and regulators may delay, limit, or reject approvals. This could delay launches or prevent new medicines and uses from reaching patients.

    From the company's own filingsWould hit how fast sales growRegeneron Pharmaceuticals, Inc. 2025 Form 10-K

  4. Coverage, reimbursement, and pricing

    Insurers and government programs may restrict coverage or reimbursement, while pricing rules and patient affordability may change. These factors can reduce use of Regeneron's medicines.

    From the company's own filingsWould hit how fast sales growRegeneron Pharmaceuticals, Inc. 2025 Form 10-K

  5. Manufacturing and supply constraints

    Regeneron relies on its own facilities, collaborators, and outside suppliers for manufacturing and other supply steps. Delays, quality problems, or insufficient capacity could disrupt supply or postpone launches.

    From the company's own filingsWould hit how fast sales growRegeneron Pharmaceuticals, Inc. 2025 Form 10-K

  6. Reliance on collaborators

    Sanofi, Bayer, and other partners contribute to development, manufacturing, or sales of some products. If an important collaboration ends or a partner fails to perform, progress and revenue could be affected.

    From the company's own filingsWould hit how fast sales growRegeneron Pharmaceuticals, Inc. 2025 Form 10-K

  7. Combined U.S. EYLEA franchise sales still declined 1%, and EYLEA HD's net selling price fell.

    From our researchWould hit how fast sales growRegeneron Q3 2026 results

Is it a good business?

From 2016 to 2025 it earned between 12% and 50% on the capital invested in it, a median of 24%. Its cost of capital in the latest valuation is 7.7%; returns were above it in every one of the 9 years.

From 2016 to 2025 it earned between 14% and 43% on its shareholders' equity, a median of 19%.

Over 10 years its operating margin ranged from 25¢ to 56¢ per sales dollar, a median of 35¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital12%
20162025

Cost of capital 7.7%

Return on equity14%
20162025
Return on invested capital is operating profit after tax (at the median effective rate, 12%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 1.5% in a year, so each remaining share owns a slightly bigger slice.

It holds $6.6B more in cash than it owes.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $952.40. Our put its value between $436.30 and $1,129.13, with $782.85 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $436.30

This scenario assumes the big jump in sales this year was partly temporary, and that falling sales of the older eye drug and future competition leave revenue roughly flat after next year, with profits staying near 2025 levels.

Base case, $782.85

This scenario assumes the strong growth of recent quarters, led by the Dupixent partnership and the newer eye drug, settles into steady mid-single-digit growth after next year, with profits a bit higher than over the past year.

Bull case, $1,129.13

This scenario assumes the surge in sales this year, driven by the Dupixent partnership, the newer eye drug and the cancer drug, is mostly lasting, so revenue keeps growing at a healthy pace and profits stay close to this year's best quarter.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects more than we do.Price above value: 22%

For Regeneron Pharmaceuticals to be worth today's $952.40, sales would need to grow about 11.5% a year. We assume 6.4%. Over the last 5 years, sales grew 4.5% a year.

−2.5%0%+2.5%+5%+7.5%+10%+12.5%+15%Past 5 yrs 4.5%We assume 6.4%Price needs 11.5%

Or, if sales grow 6.4% as we assume, the price works with a profit margin of 39.5% (we assume 32.0%).

Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.

Do you think sales can grow 11.5% a year?

Try your own numbers

We're not very sure of this range: it scores 49 out of 100 on our checks. The weakest point is historical stability.

Test the assumptions

Our base value of $782.85 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average6.4%
  • Operating margin32.0%
  • Long-term growth rate2.5%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$782.85 -17.8%

Build